Physician profile
Charles H White
NPI 1215900220
$2,348.16
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $475 · 2021: $769 · 2022: $237 · 2023: $606 · 2024: $15.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $547 · Education: $74.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.96 |
| Education | $74.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $466.71 | 2020-2023 | Breztri, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $257.14 | 2021-2023 | Dupixent |
| Insmed, INC. | $254.56 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.66 | 2020-2023 | Ofev |
| Genzyme Corporation | $189.14 | 2019-2023 | |
| Glaxosmithkline, LLC. | $180.27 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $98.56 | 2021 | |
| Grifols USA, LLC | $93.98 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $93.80 | 2019 | |
| Sanofi-Aventis U.S. LLC | $74.75 | 2023 | |
| Sunovion Pharmaceuticals INC. | $67.49 | 2019-2020 | |
| Mylan Specialty L.P. | $58.91 | 2020-2021 | |
| United Therapeutics Corporation | $56.90 | 2020-2021 | |
| Amgen INC. | $55.47 | 2023 | Tezspire |
| Abbvie INC. | $38.81 | 2023-2024 | Dalvance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $38.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.70 | 2021 | |
| Gilead Sciences, INC. | $21.26 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $19.56 | 2021 | |
| Phadia US INC. | $15.53 | 2021 | |
| Braintree Laboratories, INC. | $12.96 | 2023 | Suflave, Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.